Inventor
NI JINSONG
US23 patents
⚠️ This page may combine multiple inventors who share the name “NI JINSONG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CLOUDBREAK THERAPEUTICS LLC
11 patentsUS9987223B2Jun 5, 2018
Compositions and methods for treating pterygium
CLOUDBREAK THERAPEUTICS LLC19 citations93
US9980901B2May 29, 2018
Compositions and methods for treating pterygium
CLOUDBREAK THERAPEUTICS LLC16 citations92
US10688092B2Jun 23, 2020
Compositions and methods of using nintedanib for improving glaucoma surgery success
CLOUDBREAK THERAPEUTICS LLC9 citations84
US10335408B2Jul 2, 2019
Compositions and methods of using nintedanib for improving glaucoma surgery success
CLOUDBREAK THERAPEUTICS LLC6 citations84
US10980741B2Apr 20, 2021
Compositions and methods for treating pterygium recurrence
CLOUDBREAK THERAPEUTICS LLC5 citations83
US10149820B2Dec 11, 2018
Compositions and methods for treating pterygium
CLOUDBREAK THERAPEUTICS LLC8 citations83
US10149819B2Dec 11, 2018
Compositions and methods for treating hyperemia
CLOUDBREAK THERAPEUTICS LLC3 citations83
US12186424B2Jan 7, 2025
Compositions and methods for treating pterygium recurrence
CLOUDBREAK THERAPEUTICS LLC2 citations74
US11007214B2May 18, 2021
Compositions and methods for treating eye diseases
CLOUDBREAK THERAPEUTICS LLC2 citations73
US10744153B1Aug 18, 2020
Compositions and methods for treating meibomian gland dysfunction
CLOUDBREAK THERAPEUTICS LLC1 citations73
US11666533B2Jun 6, 2023
Emulsion formulations of multikinase inhibitors
CLOUDBREAK THERAPEUTICS LLC1 citations53
ADS THERAPEUTICS LLC
9 patentsUS11191751B1Dec 7, 2021
Topical ophthalmological atropine free base compositions
ADS THERAPEUTICS LLC17 citations85
US12491183B2Dec 9, 2025
Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
ADS THERAPEUTICS LLC1 citations74
US11246864B2Feb 15, 2022
Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
ADS THERAPEUTICS LLC3 citations72
US11166977B2Nov 9, 2021
Compositions for treating meibomian gland dysfunction
ADS THERAPEUTICS LLC1 citations72
US12156873B2Dec 3, 2024
Composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
ADS THERAPEUTICS LLC2 citations71
US12070501B1Aug 27, 2024
Topical ophthalmological compositions
ADS THERAPEUTICS LLC2 citations70
US12214049B2Feb 4, 2025
Anti-angiogenic antibody-drug conjugates
ADS THERAPEUTICS LLC1 citations63
US11911379B2Feb 27, 2024
Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
ADS THERAPEUTICS LLC0 citations62
US12485177B2Dec 2, 2025
Topical ophthalmological compositions
ADS THERAPEUTICS LLC1 citations61